Ben Markman
Impact in
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Cancer Research top 5%
Papers in
- Oncology 59
- Cancer Immunotherapy and Biomarkers 21
- Colorectal Cancer Treatments and Studies 15
- Lung Cancer Research Studies 15
- HER2/EGFR in Cancer Research 10
- Cancer Treatment and Pharmacology 9
-
- Lung Cancer Treatments and Mutations 12
- Co-authors
- Josep Tabernero (17 shared papers)Rodrigo Dienstmann (3 shared papers)José Baselga (3 shared papers)Francesco Atzori (2 shared papers)Maurizio Scaltriti (3 shared papers)Joaquı́n Arribas (1 shared paper)Michel Maira (1 shared paper)Serena Di Cosimo (1 shared paper)
- Journals
- Journal of Clinical Oncology (26 papers)Annals of Oncology (8 papers)Cancer Research (4 papers)Clinical Cancer Research (3 papers)Investigational New Drugs (3 papers)
- Partner nations
- AustraliaUnited StatesSpain
In The Last Decade
Ben Markman
72 papers receiving 2.5k citations
Ben Markman's Hit Papers
Peers
Comparison fields: 5 of 98
- Oncology 1.2k
- Cancer Research 329
- Genetics 229
- Molecular Biology 1.3k
- Pathology and Forensic Medicine 334
Countries citing papers authored by Ben Markman
This map shows the geographic impact of Ben Markman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ben Markman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ben Markman more than expected).
Fields of papers citing papers by Ben Markman
This network shows the impact of papers produced by Ben Markman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ben Markman. The network helps show where Ben Markman may publish in the future.
Co-authors
The 25 scholars most cited alongside Ben Markman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 75 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations Hit paper breakdown → | 2008 | 626 |
| 2 | 2010 | 275 | |
| 3 | 2020 | 156 | |
| 4 | 2009 | 127 | |
| 5 | 2020 | 116 | |
| 6 | 2010 | 92 | |
| 7 | 2019 | 89 | |
| 8 | 2014 | 87 | |
| 9 | A gut microbial signature for combination immune checkpoint blockade across cancer types Hit paper breakdown → | 2024 | 67 |
| 10 | 2011 | 67 | |
| 11 | 2017 | 57 | |
| 12 | 2019 | 44 | |
| 13 | Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors | 2022 | 40 |
| 14 | 2017 | 37 | |
| 15 | 2012 | 36 | |
| 16 | 2023 | 35 | |
| 17 | 2017 | 35 | |
| 18 | 2018 | 33 | |
| 19 | 2012 | 32 | |
| 20 | 2018 | 31 |
About Ben Markman
Ben Markman is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Surgery and Cancer Research, having authored 75 papers that have together received 2.5k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (21 papers), Colorectal Cancer Treatments and Studies (15 papers), Lung Cancer Research Studies (15 papers), Lung Cancer Treatments and Mutations (12 papers), HER2/EGFR in Cancer Research (10 papers), Cancer Treatment and Pharmacology (9 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). The work is most often cited by research in Oncology (1.2k citations), Cancer Research (329 citations), Genetics (229 citations), Molecular Biology (1.3k citations) and Pathology and Forensic Medicine (334 citations). Ben Markman has collaborated with scholars based in Australia, United States and Spain. Frequent co-authors include Josep Tabernero, Rodrigo Dienstmann, José Baselga, Francesco Atzori, Maurizio Scaltriti, Joaquı́n Arribas, Michel Maira, Serena Di Cosimo, Violeta Serra and Vanesa Valero. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Clinical Cancer Research and Investigational New Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.